Four highly purified synthetic peptides encompassing segments of the 68-86 region [for the numbering system used, see Eylar, E. H., Brostoff, S., Hashim, G., Caccam, J. & Burnett, P. (1971) J. Biol. Chem. 246, 5770-5784] of myelin basic protein (MBP), a region known to induce experimental allergic encephalomyelitis (EAE) in Lewis rats, were used to define and compare structure-function relationships between the primary structure of the 68-86 sequence and the three following biological activities: induction of EAE in Lewis rats, stimulation of T lymphocytes in vitro as measured by augmented cellular transfer of EAE to syngeneic recipients, and lymphocyte proliferation, as measured by [3Jthymidine incorporation. Guinea pig (GP) MBP was approximately 60 or 1500 times more active than the GP68-84 (Y G S L P Q K S Q R S Q D E N; single-letter amino acid abbreviations) or the modified bovine (MB) 68-84 (Y G S L P Q K A Q R P Q D E N) peptides for induction of EAE, respectively. Furthermore, lymphocytes primed with either GPMBP, GP68,84, or MB68-84 crossreacted in vitro with either GPMBP, GP68-84, or MB68-84 for activation of lymphocyte transfer activity. In contrast, lymphocytes primed with either GP68-84 or MB68-84 exhibited antigen-specific proliferation in vitro exclusively in response to either GP or MB sequences, respectively. Neither GP75-84 (S Q R S Q D E N) nor GP75-86 (S Q R S Q D E N P V) induced EAE, activated lymphocytes for EAE transfer, or stimulated lymphocyte proliferation under conditions and doses tested. We conclude that (i) structurally distinct determinants, reflecting existence of functionally independent classes of antigen receptors, specify encephalitogenic and proliferative responses of primed lymphocytes and (it) determinants for EAE induction, cellular transfer of EAE, and lymphocyte proliferation include amino acid residues in the 68-74 (Y G S L P Q K) sequence ofGPMBP.
[3Jthymidine incorporation. Guinea pig (GP) MBP was approximately 60 or 1500 times more active than the GP68-84 (Y G S L P Q K S Q R S Q D E N; single-letter amino acid abbreviations) or the modified bovine (MB) 68-84 (Y G S L P Q K A Q R P Q D E N) peptides for induction of EAE, respectively. Furthermore, lymphocytes primed with either GPMBP, GP68,84, or MB68-84 crossreacted in vitro with either GPMBP, GP68-84, or MB68-84 for activation of lymphocyte transfer activity. In contrast, lymphocytes primed with either GP68-84 or MB68-84 exhibited antigen-specific proliferation in vitro exclusively in response to either GP or MB sequences, respectively. Neither GP75-84 (S Q R S Q D E N) nor GP75-86 (S Q R S Q D E N P V) induced EAE, activated lymphocytes for EAE transfer, or stimulated lymphocyte proliferation under conditions and doses tested. We conclude that (i) structurally distinct determinants, reflecting existence of functionally independent classes of antigen receptors, specify encephalitogenic and proliferative responses of primed lymphocytes and (it) determinants for EAE induction, cellular transfer of EAE, and lymphocyte proliferation include amino acid residues in the 68-74 (Y G S L P Q K) sequence ofGPMBP.
Experimental allergic encephalomyelitis (EAE) is a cellmediated autoimmune response directed against autologous central nervous system myelin. Disease manifestations include clinical neurologic signs and perivascular infiltration of inflammatory mononuclear cells within the central nervous system (1, 2) . Sensitization with myelin basic protein (MBP), a major protein constituent of central nervous system compact myelin, emulsified in complete Freund's adjuvant, will produce the full clinical and histological picture of EAE in a wide variety of animal species. In Lewis rats, sensitization with MBP in complete Freund's adjuvant induces the generation of lymphocytes in peripheral lymphoid organs with the capacity to adoptively transfer EAE into syngeneic Lewis recipients (3, 4) . When lymphocytes sensitized to MBP/ complete Freund's adjuvant are cultured in medium containing MBP for 3-4 days, they exhibit an '100-fold increase in EAE transfer activity, as evidenced by transfer of the paralytic signs of EAE with as few as 107 activated lymphocytes, and a vigorous antigen-specific proliferative response, as evidenced by [3H]thymidine incorporation (5) (6) (7) (8) .
The encephalitogenic determinants responsible for EAE induction are species-specific. That is, different sequences of amino acid residues located at unique positions within the MBP molecule are critical for the induction of EAE in each mammalian species. For example, the 65-74 sequence or the 114-122 sequence of MBP selectively induce EAE in rabbits and guinea pigs, respectively (9) . Thus, the capacity of MBP in complete Freund's adjuvant to induce an encephalitogenic immune response against autologous central nervous system myelin in a given mammalian species appears to be dictated by latent, species-specific immune response genes which presumably encode antigen-receptor molecules recognizing specific MBP sequences.
The encephalitogenic region of MBP for the Lewis rat has been described and structure-function relationships have been explored by use of MBP fragments prepared by enzymatic cleavage of MBP and by use of synthetic peptides. Chou et al. (10) found that the full EAE-inducing capacity of guinea pig (GP) MBP resided in an enzymatic fragment containing the 19 COOH-terminal amino acids (-G S L P Q K S Q R S Q D E N P V V H F) of a highly encephalitogenic cleavage fragment comprising residues 44-89.I1 Further enzymatic reduction of this 69-89 sequence at either the COOH-terminus, to give peptide 69-85 (G S L P Q K S Q R S Q D E N P), or the NH2 terminus, to give peptide 73-89 (Q K S Q R S Q D E N P V V H F), resulted in an order-of-magnitude decrease in activity of both encephalitogenic peptides (11) . Cleavage of the 69-89 peptide at the arginine79-serine80 bond (G S L P Q K S Q R/S Q D E N P V V H F) abolished EAE-inducing activity (10) . From these observations, Chou et al. (11) Table 1 for an explanation of the residue numbering.
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sequence of GPMBP (P Q K S Q R S Q D E N P V) comprises the shortest possible sequence possessing the full encephalitogenic activity of MBP.
From synthetic peptides prepared by the Merrifield solidphase method on tert-butyloxycarbonylglycyl resins, Hashim (12) demonstrated that the 69-84 region was a major EAE-inducing region of MBP in the Lewis rat. Furthermore, all peptides with the GP sequence (P Q K S Q R S Q D E N G, Q K S Q R S Q D E N G, or S Q R S Q D E N G) or the modified bovine (MB) sequence (G S L P Q K A Q R P Q D EN G, P Q K A Q R P Q DEN G, or A Q R P Q DEN G) were reported to possess encephalitogenic potency comparable to that of GPMBP (12) (13) (14) . Thus, in contrast to the work reported with enzymatic fragments, deletions at the NH2 terminus up to but not including serine-75 (GP) or alanine-75 (MB) did not materially alter the encephalitogenic activity of the two synthetic nonapeptides. Hashim and co-workers (13, 14) concluded that the NH2-terminal G S L P Q K sequence was not necessary for EAE induction and that the complete determinant responsible for full EAE-inducing activity in Lewis rats resided in the 75-84 sequence of GPMBP (S Q R S Q D E N).
Definition (17, 18) showed that GPMBP and the GP114-122 encephalitogenic peptide shared EAE-inducing activity but contained separate determinants for cell-mediated responses associated with development of disease. These findings were consonant with the concept of two determinants acting synergistically for induction of EAE.
For our work using immunopharmacological and proteinbinding techniques to define molecular interactions of EAEinducing MBP determinants and their respective receptors on Lewis rat lymphoid cells, securing and testing highly purified synthetic peptides of minimal length containing these determinants was a crucial first step. To this end, we obtained four synthetic peptides consisting of sequences analogous to the reported minimal length encephalitogenic determinant (GP75-84) (13) or with the sequence extensions at either the COOH terminus (GP75-86) or the NH2 terminus (GP68-84 or MB68-84) reported to increase the potency of encephalitogenic immune responses in Lewis rats (11) . We tested each peptide for its capacity to induce EAE and its ability to stimulate the two EAE-associated lymphocyte responses paralleling the encephalitogenic immune response: (i) in vitro activation of lymphoid cells expressing EAE-transfer activity, corresponding to in vivo triggering of encephalitogenic effector lymphocytes, and (ii) in vitro proliferation of lymphocytes, corresponding to in vivo expansion of the EAEinducing lymphocyte population. Our observations suggest that (a) determinants specifying the encephalitogenic activity of lymphocytes are structurally distinct from determinants engendering in vitro lymphocyte proliferation and (b) determinants for EAE induction, in vitro activation of cells transferring EAE, and in vitro proliferation of lymphocytes include amino acid residues in the 68-74 sequence of GPMBP (Y G S L P Q K).
MATERIALS AND METHODS
Animals. Adult male Lewis rats (8-12 weeks old, 200-225 g) were purchased from M. A. Bioproducts, Walkersville, MD. Rats were housed 6-7 per cage with pine shavings for bedding and were given free access to food and water.
Antigens. GPMBP was isolated from spinal cord by the method of Swanborg et al. (19) . A high degree of homogeneity of each MBP preparation was confirmed by polyacrylamide gel electrophoresis. Lysozyme (Sigma) was used as a control antigen because its molecular weight and isoelectric point are similar to those of MBP.
The designation, primary structure, and other pertinent features of the four synthetic peptides used in this investigation, together with the corresponding structure of the relevant region of GPMBP under study, are listed in Table 1 (20) for native bovine MBP, containing glycine and histidine at positions 77 and 78, respectively. Molecular weights are that published for MBP (1, 20) and those calculated on the basis of amino acid sequences for the synthetic peptides. The HPLC data for each peptide were obtained using isocratic elution with the indicated percentage of solvent B [CH3CN/0.5% H3PO4 (3:2, vol/vol)] in water.
The capacity factor, kn, is described in Materials and Methods.
volume from the time of injection to the unretained solvent peak (22 (23) .
Clinical and histopathological measurements ofEAE. Rats were monitored daily for clinical signs of EAE according to the following scale: lack oftonicity in the distal halfofthe tail, 0.25; lack of tonicity in the entire tail, 0.5; ataxia, 1.0; hindleg paresis, 2.0; and hindleg paralysis, 3.0. Sections of brain and spinal cord were examined microscopically for EAE lesions and the lesions were graded (with a maximal value of 3.0) as described by Carbone et al. (24) .
In Vitro Culture and Adoptive Transfer of Lymphocytes. Nine to eighteen days after sensitization, the popliteal, inguinal, and periaortic lymph nodes or the spleens were trimmed of fat and processed to a single-cell suspension by teasing through a stainless steel wire mesh screen. The cells were washed three times in Hanks' balanced salts solution (GIBCO) and resuspended in complete RPMI 1640 medium (Northwestern University, Chicago, IL) containing 5% fetal bovine serum (GIBCO), 2 mM glutamnine (Sigma), streptomycin (100 ,ug/ml) (GIBCO), penicillin (100 units/ml) (GIBCO), and 2-mercaptoethanol (Eastman-Kodak). Cells were adjusted to a density of 5 x 106 per ml and incubated 84 hr at 37.5°C with 5% CO2 and the designated antigen in 75-cm2 culture flasks (Corning). Each Table 4 . Lymphocytes primed with GPMBP or GP68-84 exhibited significantly increased incorporation of [3H]thymidine when cultured with GPMBP or GP68-84 (SI = 5-50); no appreciable increase was observed when these cells were cultured with MB68-84 (SI < 1.5). Conversely, lymphocytes sensitized to M1368-84 were stimulated to incorporate thymidine by culture with MB68-84 (SI = 5-15) but not with GPMBP or GP68-84 (SI < 2). The GP75-84 and GP75-86 peptides did not stimulate [3H]thymidine incorpo- Tables 3 and 4) . Second, determinants for EAE induction and both in vitro immune responses include amino acid residues in the 68-74 (-Y G S L P Q K-) sequence of GPMBP (see Tables 2-4) .
From an autoreactive standpoint, any encephalitogenic determinant(s) present in any MBP species must crossreact with rat MBP in order to induce EAE or to stimulate cellular transfer ofthe disease in the Lewis rat. In our hands, the MBP and peptide preparations possessing encephalitogenic activity crossreacted with rat MBP in terms of in vitro activation of cells effecting transfer of the disease (see Table 3 and text related to Table 3 ). In contrast, the proliferative determinant in the encephalitogenic MB68-84 peptide exhibited no detectable crossreactivity with GP68-84, GPMBP, or rat MBP in the lymphocyte thymidine-incorporation assay (see Table  4 and related text). Thus, either one or both of the amino acid differences between the GP68-84 and MB68-84 peptides [Y G S L P Q K (S/A) Q R (S/P) Q D E N] encoded the exquisite specificity of the proliferative determinant(s), whereas neither residue had any appreciable influence upon the specificity of the determinant(s) responsible for activation of cellular transfer. From such observations, we conclude that the in vitro activation of cells involves a determinant-specific receptor on lymphocytes that is directly implicated in mediating transfer of EAE, whereas the in vitro proliferative response reflects an equally determinant-specific but entirely separate set of antigen receptors. Our findings are consonant with work of others (13) (14) (15) (16) that suggests that two functionally disparate determinants may need to act in concert for development of EAE. Our results reduce this concept to the level of specific amino acid sequences and residues within the rat-specific encephalitogenic region of GPMBP.
In several instances, we observed a clear-cut dissociation of in vitro activation and in vitro proliferative immune responses of primed lymphocytes. That is, lymph node cells or splenocytes sensitized to GP68-84 or MB68-84 manifested transfer of EAE after activation with MB68-84 or GP68-84, respectively (see Table 3 ), without detectable antigen-specific proliferation (see Table 4 ). These findings underscore the fact that in vitro cellular proliferation is not a necessary concomitance of in vitro T-lymphocyte activation resulting in transfer of EAE.
A second major observation reported here is that the 68-74 (-Y G S L P Q K-) sequence of rat MBP was essential for, or greatly augmented, autoreactivity to MBP. Our observation that the determinant(s) enabling proliferative responses include immunodominant amino acid residues at positions 75 or 80 (-X Q R X Q D E N-) along with other research indicating that determinant(s) stimulating encephalitogenic processes include asparagine-84 (-S Q R S Q D E N-) (25) , indicates that structurally distinct proliferative and encephalitogenic determinants are located within the 75-84 sequence and that both require the 68-74 (-Y G S L P Q K-) sequence for expression of the respective activities. There are at least four interpretations for these findings. First, the -Y G S L P Q K-sequence may stabilize a conformation necessary for immune recognition of the -S Q R S Q D E N-sequence. Second, the proliferative and encephalitogenic determinants may include separate or possibly overlapping regions in the -Y G S L P Q K-sequence. Third, another independent determinant confined to this sequence may be required for the expression of both encephalitogenic and proliferative determinant activities. Fourth, the -Y G S L P Q K-sequence may facilitate the interaction ofencephalitogenic peptides with antigen-presenting cells necessary for T-cell recognition.
In terms of encephalitogenic activity, the GP68-84 peptide *was about 1/60th as active as GPMBP and, thus, does not represent the minimal sequence associated with full encephalitogenic activity. This finding is consistent with the work of Chou et al. (11) showing that cleavage of the 86-89 (-V V H F-) sequence from the 69-89 peptide fragment resulted in a 90% reduction of encephalitogenic activity. The GP75-86 peptide did not induce EAE at a dose of 50 ,g per rat (Table 2 ). Additional testing of the GP75-86 peptide at very high doses will be necessary to determine whether the augmenting effect of the 85-86 (-P V-) sequence is dependent upon the presence of the 68-74 (-Y G S L P Q K-) sequence.
We have found that the GP75-84 (S Q R S Q D E N) peptide lacks encephalitogenic activity, even when tested in doses as high as 100 Ag per rat (Table 2 ). In addition, we have found that the MB68-84 peptide has less encephalitogenic activity than might have been expected from the work reported by Hashim and his associates (12, 13) . It is noteworthy that the synthetic peptides S53 and S49 (S Q R S Q D E N G and G S L P Q K A Q R P Q D E N G, respectively), reported by Hashim's group (12, 13) to possess EAE activity for Lewis rats, differ from peptides GP75-84 and MB68-84, respectively, by virtue of containing a COOH-terminal glycine. Whether the non-native COOH-terminal glycine confers either demonstrable or increased encephalitogenic activity, respectively, on GP75-84-glycine or MB68-84-glycine should be investigated.
